Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484502 | 1.00 | MAPT (0.48) | MAPTL3MBTL1DPP4KMT2APOLB | |
| SCHEMBL18583728 | 1.00 | MAPT (0.48) | MAPTL3MBTL1DPP4KMT2APOLB | |
| SCHEMBL29333661 | 0.86 | MAPT (0.41) | MAPTL3MBTL1DPP4KMT2APOLB | |
| SCHEMBL3751829 | 0.83 | MAPT (0.57) | MAPTL3MBTL1KMT2APOLBLMNA | |
| SCHEMBL19262494 | 0.83 | MAPT (0.57) | MAPTL3MBTL1KMT2APOLBLMNA | |
| SCHEMBL26075213 | 0.83 | MAPT (0.57) | MAPTL3MBTL1KMT2APOLBLMNA | |
| SCHEMBL29349103 | 0.78 | MAPT (0.47) | MAPTL3MBTL1DPP4KMT2APOLB | |
| SCHEMBL12280153 | 0.78 | MAPT (0.47) | MAPTL3MBTL1DPP4KMT2APOLB | |
| SCHEMBL13663383 | 0.78 | MAPT (0.47) | MAPTL3MBTL1DPP4KMT2APOLB | |
| SCHEMBL23806425 | 0.77 | MAPT (0.47) | MAPTL3MBTL1DPP4POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220289691-A1 | 5-AMINO-SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289691-A1 | 5-AMINO-SUBSTITUTED PYRAZOLES AND TRIAZOLES AS PEST CONTROL AGENTS | API5, AAAS, AADAC | MAPT 3273/4885L3MBTL1 232/4885DPP4 1281/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | MAPT 718/4885L3MBTL1 4152/4885DPP4 2782/4885 |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | MAPT 3710/4885L3MBTL1 899/4885DPP4 172/4885 |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | MAPT 3676/4885L3MBTL1 4879/4885DPP4 1029/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | MAPT 4079/4885L3MBTL1 681/4885DPP4 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.